1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019; 10:63–89.
Article
2. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012; 2012:152–6.
Article
3. Jung KW, Won YJ, Hong S, Kong HJ, Im JS, Seo HG. Prediction of cancer incidence and mortality in Korea, 2021. Cancer Res Treat. 2021; 53:316–22.
Article
4. Moyer VA; US. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157:120–34.
Article
5. Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2017; 14:26–37.
Article
6. Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA. 2017; 317:1949–50.
Article
7. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 2020; 52:335–50.
Article
8. Baldwin LM, Andrilla CH, Porter MP, Rosenblatt RA, Patel S, Doescher MP. Treatment of early-stage prostate cancer among rural and urban patients. Cancer. 2013; 119:3067–75.
Article
9. Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. Eur Urol. 2017; 71:729–37.
Article
10. Xia L, Talwar R, Chelluri RR, Guzzo TJ, Lee DJ. Surgical delay and pathological outcomes for clinically localized high-risk prostate cancer. JAMA Netw Open. 2020; 3:e2028320.
Article
11. Yoo S, Oh S, Park J, Cho SY, Cho MC, Jeong H, et al. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men. BJU Int. 2019; 123:140–8.
Article
12. Park J, Suh B, Shin DW, Hong JH, Ahn H. Changing patterns of primary treatment in Korean men with prostate cancer over 10 years: a nationwide population based study. Cancer Res Treat. 2016; 48:899–906.
Article
13. Lee SY, Jung KY, Lee IK, Yi SD, Cho YW, Kim DW, et al. Prevalence of treated epilepsy in Korea based on national health insurance data. J Korean Med Sci. 2012; 27:285–90.
Article
14. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997; 277:467–71.
Article
15. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014; 15:e484–92.
Article
16. Van Poppel H, Roobol MJ, Chapple CR, Catto JW, N’Dow J, Sonksen J, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur Urol. 2021; 80:703–11.
Article
17. Rapiti E, Fioretta G, Schaffar R, Neyroud-Caspar I, Verkooijen HM, Schmidlin F, et al. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer. 2009; 115:5556–65.
Article
18. Aarts MJ, Koldewijn EL, Poortmans PM, Coebergh JW, Louwman M. The impact of socioeconomic status on prostate cancer treatment and survival in the southern Netherlands. Urology. 2013; 81:593–9.
Article
19. Lee DH, Jung HB, Chung MS, Lee SH, Chung BH. The change of prostate cancer treatment in Korea: 5 year analysis of a single institution. Yonsei Med J. 2013; 54:87–91.
Article
20. Mottet N, van den Bergh RC, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021; 79:243–62.
21. Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A. First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis. 2009; 12:355–60.
Article
22. Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev. 2005; 14:590–5.
Article
23. Afshar N, English DR, Milne RL. Rural-urban residence and cancer survival in high-income countries: a systematic review. Cancer. 2019; 125:2172–84.
Article
24. Arcury TA, Gesler WM, Preisser JS, Sherman J, Spencer J, Perin J. The effects of geography and spatial behavior on health care utilization among the residents of a rural region. Health Serv Res. 2005; 40:135–55.
Article
25. Cary C, Odisho AY, Cooperberg MR. Variation in prostate cancer treatment associated with population density of the county of residence. Prostate Cancer Prostatic Dis. 2016; 19:174–9.
Article
26. Lee J. Health inequality in health checkups. Korean J Fam Med. 2018; 39:65–6.
Article
27. Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL. Geographic distribution and survival outcomes for rural ppatients with cancer treated in clinical trials. JAMA Netw Open. 2018; 1:e181235.